Add On Effect Of Basti In Non-Alcoholic Fatty Liver Disease.

Phase 2

• Conditions: Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

• Registration Number: CTRI/2024/03/064543
• Lead Sponsor: All India Institute Of Ayurveda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Previously diagnosed and newly diagnosed case of NAFLD (fatty liver grade 1 or 2) confirmed by

Sonography (USG Or Fibroscan)

2.Grade 1 & Grade 2 NAFLD in USG Or F0 to F2 Less Than 10kPa Score,CAP Score -S1 248-260db per m,S2

260-290 db per m,IQR per M-30 Percent or less in Fibroscan.

3.Patients willing to participate in the clinical trial.

Exclusion Criteria

1.Patent having NASH/NAFLD associated with Metabolic diseases

2. Patients having NAFLD Grade 3 Or More

3. Patients with Type 2 diabetes

4. Known case of Hypertension

5. Known case of hypothyroidism or hyperthyroidism

6. Patients having BMI Greater than 30,

7. Patients having deranged liver functions (AST per ALT Greater than 2 folds). Patients suffering from Hepatitis,

Cirrhosis of liver, Ascites, Portal hypertension (PTH), patient having other chronic liver diseases,

etc.

8. Patients having deranged renal functions Or chronic kidney diseases.

9. Patients suffering from AIDS, Tuberculosis and other infectious diseases.

10. Any Malignancy.

11. Pregnant and lactating women.

12. Patient on long term medication (Hepatotoxic medication like NSAID, Rifampicin,steroid).

13. Patients consuming Alcohol or other narcotic substance.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes In Sonography Findings (Expecting From Grade II To Grade I Or 0 And From Grade I To Grade 0) Along With Changes In Clinical Presentations (Expecting 5% To 10% Reductions In Signs And Symptoms).Timepoint: Day 1 <br/ ><br>30 Days <br/ ><br>60 Days

Secondary Outcome Measures

Name	Time	Method
1 Changes In Waist Circumference <br/ ><br> 2 Changes In Liver Function Tests <br/ ><br> 3 Changes In Lipid Profile <br/ ><br> 4 Changes In Vitamin D Level <br/ ><br> 5 Improvement In Quality Of Life.Timepoint: Day 1 <br/ ><br>Day 30 <br/ ><br>Day 60